“Leave nothing but your footprints,” says the notice at the local beach, its message intended to encourage bathers and picnickers to keep the environment clean and clear of their waste. It’s not a directive, more a gentle instruction and a polite way of reminding individuals of their collective responsibilities.
The E In ESG: The Provider’s View Of Sustainability Compliance
Reusable Or Disposable Devices? And How Does That Square With Quality Care And Sustainability?
As the health care sector moves from linear to circular, medtechs, providers and patients all have roles to play in ensuring that current strategies, practices and behaviors contribute to guarantee a sustainable future. Part one of a short series on this theme looks as best practice for providers.
More from ESG
• By
Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.
• By
Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.
• By
As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment.
• By
Royal Philips is at the forefront of the driving environmental sustainability along the Scope 1-2-3 chain. The company hosted a round table in Amsterdam to hear experiences from providers.
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.